Relative Roles of Natural Killer- and T Cell-Mediated Anti-Leukemia Effects in Chronic Myelogenous Leukemia Patients Treated with Interferon-α

References

• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J.M., Gutterman J.U. Interferon-alpha produces sustained cyto-genetic responses in chronic inyelogenous leukemia. Philadelphia chromosome-positive patients. Ann. Intern. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Tura S., Baccarani M., Zuffa E., et al. Interferon Alfa-2A as compared with conventional chemotherapy for the treatment of Chronic Myeloid Leukemia. N. Engl. J. Med. 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Schmidt H., Steinke B., Zinser R., et al. Interferon a in the treatment of chronic myeloid leukemia and essential thrombocy-tosis: differences in response rate between untreated patients and patients pretreated with busulfan. Tumor Diagn. Ther. 1989; 10: 257–261
   Google Scholar
• VonWussow P., Pralle H., Hochkeppel H.K., et al. Effective Natural Interferon-alpha Therapy in Recombinant Interferon-alpha Resistant Patients with Hairy Cell Leukemia. Blood 1991; 78: 3843
   Google Scholar
• Herrmann F., Helfrich S.G., Lindemann A., Schleiermacher E., Huber C., Mertelsmann R. Elevated Circulating Levels of Tumor Necrosis Factor Predict Unresponsiveness to Treatment with Interferon Alfa-2b in Chronic Myelogenous Leukemia. J. Clin. Oncol. 1992; 10: 631–634
   PubMed Web of Science ®Google Scholar
• Oguma N., Shigeta C, Takauchi K., et al. Molecular Elimination of the Minimal Residual Ph1 Clone with IFNalpha in CML. Lancet. 1992; 339: 557–558
   PubMed Web of Science ®Google Scholar
• Gresser I., Carnaud C., Maury C., et al. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after Interferon αβ treatment in mice. J. Exp. Med. 1991; 173: 1193–1203
   PubMed Web of Science ®Google Scholar
• Galvani D.W., Cawley J.C. Mechanism of action of α interferon in chronic granulocytic leukaemia: Evidence for preferential inhibition of late progenitors. Br. J. Haematol. 1989; 73: 475–479
   PubMed Web of Science ®Google Scholar
• Dowding C., Guo A.P., Osterholz J., Siczkowski M., Goldman J., Gordon M. Interferon-alpha Overrides the Deficient Adhesion of Chronic Myeloid Leukemia Primitive Progenitor Cells to Bone Marrow Stromal Cells. Blood 1991; 78: 499–505
   PubMed Web of Science ®Google Scholar
• Galvani D.W., Owens W., Nethersell A.B.W., Cawley J.C. The beneficial effects of αIFN in CGL are probably not mediated by NK cells. Br. J. Haematol. 1989; 71: 233–237
   PubMed Web of Science ®Google Scholar
• Pawelec G., Schneider E., Ehninger G., Rehbein A., Schmidt H. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-α (Wellferon). Cancer Immunol. Immunother. 1989; 29: 63–66
   PubMed Web of Science ®Google Scholar
• Ellis T.M., McKenzie R.S., Simms P.E., Helfrich B.A., Fisher R.I. Induction of human lymphokine-activated killer cells by IFN-α and IFN-gamma. J. Immunol. 1989; 143: 4282–4286
   PubMed Web of Science ®Google Scholar
• Meseri A., Delwail V., Brizard A., et al. Endogenous Lymphokine Activated Killer Cell Activity and Cytogenetic Response in Chronic Myelogenous Leukaemia Treated with alpha-Interferon. Br. J. Haematol. 1993; 83: 218–222
   PubMed Web of Science ®Google Scholar
• Bergmann L., Weidmann E., Bungert B., Hechler P., Mitrou P.S. Influence of various cytokines on the induction of lymphokine-activated killer cells. Nat. Immun. Cell Growth Regul. 1990; 9: 265–273
   PubMedGoogle Scholar
• Holan V., Kohno K., Minowada J. Natural Human Interferon-alpha Augments Interleukin-2 Production by a Direct Action on the Activated IL-2-Producing T-Cells. J. Interferon Res. 1991; 11: 319–325
   PubMedGoogle Scholar
• Muller C.A., Walz J., Zinser R., Buhring H.J., Steinke B., Schmidt H. In Vivo Induction of HLA Molecules in Patients with Myeloproliferative Syndrome during IFNalpha Treatment. Ann. Hematol. 1991; 63: 259–263
   PubMed Web of Science ®Google Scholar
• Schmidt H., Kellermann-Kegreiss E., Steiert I., Walz J., Zinser R., Muller C.A. Differential Regulation of Human Leukocyte Antigen Class-I Genes by Interferon Invivo and Invitro. J. Immunother. 1993; 14: 169–174
   Web of Science ®Google Scholar
• Morecki S., Revelvilk S., Nabet C., et al. Immunological Evaluation of Patients with Hematological Malignancies Receiving Ambulatory Cytokine-Mediated Immunotherapy with Recombinant Human Interferon-alpha2a and Interleukin-2. Cancer Immunol. Immunother. 1992; 35: 401–411
   PubMed Web of Science ®Google Scholar
• Meloni G., Foà R., Tosti S., Vignetti M., Gavosto F., Mandelli F. IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: A pilot study. Haematologica (Pavia) 1990; 75: 502–505
   PubMedGoogle Scholar
• Ogata K., Yokose N., Ito T., An E., Dan K., Nomura T. Effects of Interleukin-2 on Myelodysplastic Syndromes. Leuk. Res. 1993; 17: 137–142
   PubMed Web of Science ®Google Scholar
• Sandrelli A., De Fabritiis P., Dinucci G.D., Simone F., Dimatteo G., Mandelli F. Invitro Antitumor Effect of LAK Cells and Alpha-Interferon in Combination on Tumor Cell Lines. J. Biol. Regular. Homeost. Agent 1992; 6: 93–98
   PubMed Web of Science ®Google Scholar
• Mehta S., Flanagan P., Blackinton D., Wanebo H. Lymphokine-Activated Effector Cells—Modulation of Activity by Cytokines. Lymphokine Cytokine Res. 1992; 11: 73–77
   PubMedGoogle Scholar
• Stötter H., Custer M.C., Bolton E.S., Guedez L., Lotze M.T. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J. Immunol. 1991; 146: 150–155
   PubMed Web of Science ®Google Scholar
• Alderson M.R., Sassenfeld H.M., Widmer M.B. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 1990; 172: 577–587
   PubMed Web of Science ®Google Scholar
• Chazen G.D., Pereira Le G.M.B., Gros G., Gillis S., Shevach E.M. Interleukin 7 is a T-cell growth factor. Proc. Natl. Acad. Sci. USA 1989; 86: 5923–5927
   PubMed Web of Science ®Google Scholar
• Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-ver-sus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Chen W., Peace D.J., Rovira D.K., You S.G., Cheever M.A. T-cell Immunity to the Joining Region of p210BCR-ABL Protein. Proc. Natl. Acad. Sci. USA 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Pawelec G., Schmidt H., Rehbein A., Busch F. Anti-tumour activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside. Cancer Immunol. Immunother. 1989; 29: 242–246
   PubMed Web of Science ®Google Scholar
• Pawelec G., Reutter M., Owsianowsky M., Rehbein A., Busch F.W. Cytotoxic and noncytotoxic mechanisms of the in vitro anti-chronic myelogenous leukaemia (CML) effects of T cell clones derived from a CML patient after treatment in vivo with interferona. Cancer Immunol. Immunother. 1991; 33: 54–60
   PubMed Web of Science ®Google Scholar
• Max H., Halder T., Kropshofer H., Kalbus M., Muller C.A., Kalbacher H. Characterization of peptides bound to extra-and intracellular HLA-DR molecules. Hum. Immunol. 1993; 38: 193–200
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P.P., Pelicci P.G., Parmiani G. Human CD4 Lymphocytes Specifically Recognize a Peptide Representing the Fusion Region of the Hybrid Protein pmlRARalpha Present in Acute Promyelocytic Leukemia Cells. Blood 1993; 81: 1369–1375
   PubMed Web of Science ®Google Scholar
• Pawelec G., Schmidt H., Schneider E., Buhring H.J., Ehninger G. Cellular immunological defects of chronic myelogenous leukaemia: partial dependence on busulphan therapy. Cancer Immunol. Immunother. 1988; 27: 89–94
   PubMed Web of Science ®Google Scholar
• Pawelec G., Ehninger G., Schmidt H., et al. Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon—treated chronic myelogenous leukemia patients. Cancer Immunol. Immunother. 1990; 32: 167–172
   PubMed Web of Science ®Google Scholar
• Pawelec G., Kalbacher H., Bruserud Ø. Tumor-Specific Antigens Revisited - Presentation to the Immune System of Fusion Peptides Resulting Solely from Tumor-Specific Chromosomal Translocations. Oncol. Res. 1992; 4: 315–320
   PubMed Web of Science ®Google Scholar
• Pawelec G. Report on the 8th Maimonides Conference on Cancer Research, February 22–26, Ein Gedi, Israel. Cancer Biotherapy 1993; 8: 181–186
   PubMedGoogle Scholar